Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKinsey
Express Scripts
Harvard Business School
McKesson

Last Updated: May 28, 2022

Bevacizumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Shanghai Minimally Invasive Surgery CenterPhase 1/Phase 2
Taiwan Leader Biotech Corp.Phase 1/Phase 2
The First Affiliated Hospital of Zhengzhou UniversityPhase 1/Phase 2

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11
Ravgen, Inc. v. Myriad Genetics, Inc.2020-12-20

See all bevacizumab litigation

PTAB Litigation
PetitionerDate
Illumina, Inc.2021-07-20
Laboratory Corporation of America Holdings2021-05-28
Quest Diagnostics Incorporated2021-04-15

See all bevacizumab litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Patent Expiration
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2033-10-12
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2035-07-31
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2028-07-08
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2028-07-08
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2032-09-17
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2034-04-23
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2030-08-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Patent Expiration

2) High Certainty: US Patents for bevacizumab Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genentech, Inc. AVASTIN bevacizumab Injection 125085 See Plans and Pricing 2014-01-25 Company disclosures
Genentech, Inc. AVASTIN bevacizumab Injection 125085 See Plans and Pricing 2020-08-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for bevacizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

International Patents for bevacizumab

Country Patent Number Estimated Expiration
Norway 319867 See Plans and Pricing
Japan 4115517 See Plans and Pricing
Norway 2017040 See Plans and Pricing
Germany 69419721 See Plans and Pricing
European Patent Office 0678122 See Plans and Pricing
Norway 2006008 See Plans and Pricing
World Intellectual Property Organization (WIPO) 9416094 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
23/2006 Austria See Plans and Pricing PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
06C0024 France See Plans and Pricing PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
SZ 23/2006 Austria See Plans and Pricing PRODUCT NAME: NATALIZUMAB
C300238 Netherlands See Plans and Pricing PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
CA 2006 00025 Denmark See Plans and Pricing PRODUCT NAME: NATALIZUMAB
122006000043 Germany See Plans and Pricing PRODUCT NAME: NATALIZUMAB; NAT. REGISTRATION NO/DATE: EU /1/06/346/001 20060627; FIRST REGISTRATION: EU EU/1/06/346/001 20060627
2006C/035 Belgium See Plans and Pricing PRODUCT NAME: NATALIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/06/346/001 20060628
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
McKinsey
Dow
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.